Streetbeat News

Stock Prices

TWOU

2U has entered into a strategic agreement with its debtholders to eliminate over 50% of its debt and infuse approximately $110 million of new capital. This move will allow 2U to invest further in its mission without any interruption to its educational programs and services.

Portfolio Pulse from Benzinga Newsdesk

July 25, 2024 | 7:04 am

TSLA

Elon Musk's Grok AI chatbot will soon extend its profile analysis feature to iOS and Android platforms, currently available only to X Premium desktop users. This feature provides AI-generated summaries of user profiles, aiding in identifying bots and manipulative accounts. Musk also announced that Grok 2 is in the bug-fixing stage and will be released next month, with Grok 3 expected by December. Additionally, Musk conducted a poll on X about Tesla investing in Grok’s parent company, receiving support from market experts.

Portfolio Pulse from Ananya Gairola

July 25, 2024 | 7:00 am

UL

Unilever expects underlying sales growth of 3%-5% for 2024, driven mainly by volume. The operating margin is projected to be at least 18%, with increased brand investment. The first half saw strong gross margin progression due to volume leverage, mix, and net productivity, but this is not expected to repeat in the second half.

Portfolio Pulse from Benzinga Newsdesk

July 25, 2024 | 6:44 am

AZN

AstraZeneca has raised its 2024 guidance, now expecting total revenue and core EPS to increase by a mid-teens percentage, up from the previously anticipated low double-digit to low-teens percentage. This is due to strong growth in product sales and alliance revenue.

Portfolio Pulse from Benzinga Newsdesk

July 25, 2024 | 6:34 am

AZN

AstraZeneca (NASDAQ:AZN) reported Q2 adjusted EPS of $0.99, missing the $1.20 estimate, but sales of $12.98B beat the $12.75B estimate. EPS decreased by 7.91% YoY, while sales increased by 13.73% YoY.

Portfolio Pulse from Benzinga Newsdesk

July 25, 2024 | 6:28 am

INDV

Indivior PLC has announced a new $100 million share repurchase program, expected to be completed within six months. The program aims to repurchase Indivior's ordinary shares and is set to be completed by the end of July.

Portfolio Pulse from Benzinga Newsdesk

July 25, 2024 | 6:13 am

INDV

Indivior (NASDAQ:INDV) reported Q2 earnings per share of $0.44, significantly beating the analyst estimate of $0.14. The company also reported sales of $299 million, surpassing the $296.05 million estimate. Both earnings and sales showed year-over-year growth.

Portfolio Pulse from Benzinga Newsdesk

July 25, 2024 | 6:09 am

BABA

JD

PDD

China's central bank, the PBOC, has conducted an unscheduled lending operation, issuing 200 billion yuan in one-year loans at a reduced rate of 2.30%. This move aims to support the economy amid deflationary pressures and weak consumer demand. The U.S. Federal Reserve is likely to hold rates steady at the upcoming FOMC meeting.

Portfolio Pulse from Benzinga Neuro

July 25, 2024 | 6:01 am

STLA

Stellantis (NYSE:STLA) reported a significant decline in its half-year earnings and sales. The company's EPS dropped by 31.9% to $2.54 from $3.73 YoY, and sales decreased by 14.63% to $91.53 billion from $107.21 billion YoY.

Portfolio Pulse from Benzinga Newsdesk

July 25, 2024 | 5:58 am

SNY

TEVA

Teva and Sanofi have accelerated the enrollment for their Phase 2b trial of duvakitug (anti-TL1A) for treating inflammatory bowel disease (IBD), with topline results now expected in Q4 2024. This collaboration aims to develop and commercialize the treatment for moderate-to-severe ulcerative colitis (UC) and Crohn's disease (CD).

Portfolio Pulse from Benzinga Newsdesk

July 25, 2024 | 5:47 am